{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T11:44:18Z","timestamp":1792842258763,"version":"4.5.0"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2022,6,28]],"date-time":"2022-06-28T00:00:00Z","timestamp":1656374400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2022,6,28]],"date-time":"2022-06-28T00:00:00Z","timestamp":1656374400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Pharmacokinet"],"published-print":{"date-parts":[[2022,9]]},"DOI":"10.1007\/s40262-022-01139-w","type":"journal-article","created":{"date-parts":[[2022,6,28]],"date-time":"2022-06-28T05:02:29Z","timestamp":1656392549000},"page":"1271-1284","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["First-in-Patient Phase I\/II Study of Upacicalcet in Japanese Patients with Secondary Hyperparathyroidism Undergoing Hemodialysis: Pharmacokinetic and Pharmacodynamic Properties"],"prefix":"10.1007","volume":"61","author":[{"given":"Junichiro James","family":"Kazama","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fumihiko","family":"Koiwa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keitaro","family":"Yokoyama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masafumi","family":"Fukagawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenji","family":"Asano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5624-7553","authenticated-orcid":false,"given":"Daisuke","family":"Honda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tadao","family":"Akizawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,6,28]]},"reference":[{"issue":"4","key":"1139_CR1","doi-asserted-by":"publisher","first-page":"913","DOI":"10.2215\/CJN.06040710","volume":"6","author":"J Cunningham","year":"2011","unstructured":"Cunningham J, Locatelli F, Rodriguez M. Secondary hyperparathyroidism: pathogenesis, disease progression, and therapeutic options. Clin J Am Soc Nephrol. 2011;6(4):913\u201321. https:\/\/doi.org\/10.2215\/CJN.06040710.","journal-title":"Clin J Am Soc Nephrol"},{"issue":"9684","key":"1139_CR2","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1016\/S0140-6736(09)60507-9","volume":"374","author":"WD Fraser","year":"2009","unstructured":"Fraser WD. Hyperparathyroidism. Lancet. 2009;374(9684):145\u201358. https:\/\/doi.org\/10.1016\/S0140-6736(09)60507-9.","journal-title":"Lancet"},{"issue":"3","key":"1139_CR3","doi-asserted-by":"publisher","first-page":"1187","DOI":"10.1046\/j.1523-1755.2001.0590031187.x","volume":"59","author":"WG Goodman","year":"2001","unstructured":"Goodman WG, Goodman WG. Recent developments in the management of secondary hyperparathyroidism. Kidney Int. 2001;59(3):1187\u2013201. https:\/\/doi.org\/10.1046\/j.1523-1755.2001.0590031187.x.","journal-title":"Kidney Int"},{"issue":"3","key":"1139_CR4","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1111\/1744-9987.12058","volume":"17","author":"M Fukagawa","year":"2013","unstructured":"Fukagawa M, Yokoyama K, Koiwa F, Taniguchi M, Shoji T, Kazama JJ, CKD-MBD Guideline Working Group; Japanese Society for Dialysis Therapy, et al. Clinical practice guideline for the management of chronic kidney disease-mineral and bone disorder. Ther Apher Dial. 2013;17(3):247\u201388. https:\/\/doi.org\/10.1111\/1744-9987.12058.","journal-title":"Ther Apher Dial"},{"issue":"3","key":"1139_CR5","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1097\/01.asn.0000050224.03126.ad","volume":"14","author":"LD Quarles","year":"2003","unstructured":"Quarles LD, Sherrard DJ, Adler S, Rosansky SJ, McCary LC, Liu W, et al. The calcimimetic AMG 073 as a potential treatment for secondary hyperparathyroidism of end-stage renal disease. J Am Soc Nephrol. 2003;14(3):575\u201383. https:\/\/doi.org\/10.1097\/01.asn.0000050224.03126.ad.","journal-title":"J Am Soc Nephrol"},{"issue":"15","key":"1139_CR6","doi-asserted-by":"publisher","first-page":"1516","DOI":"10.1056\/NEJMoa031633","volume":"350","author":"GA Block","year":"2004","unstructured":"Block GA, Martin KJ, de Francisco AL, Turner SA, Avram MM, Suranyi MG, et al. Cinacalcet for secondary hyperparathyroidism in patients receiving hemodialysis. N Engl J Med. 2004;350(15):1516\u201325. https:\/\/doi.org\/10.1056\/NEJMoa031633.","journal-title":"N Engl J Med"},{"issue":"3","key":"1139_CR7","doi-asserted-by":"publisher","first-page":"800","DOI":"10.1681\/ASN.2004060512","volume":"16","author":"JS Lindberg","year":"2005","unstructured":"Lindberg JS, Culleton B, Wong G, Borah MF, Clark RV, Shapiro WB, et al. Cinacalcet HCl, an oral calcimimetic agent for the treatment of secondary hyperparathyroidism in hemodialysis and peritoneal dialysis: a randomized, double-blind, multicenter study. J Am Soc Nephrol. 2005;16(3):800\u20137. https:\/\/doi.org\/10.1681\/ASN.2004060512.","journal-title":"J Am Soc Nephrol"},{"issue":"5","key":"1139_CR8","doi-asserted-by":"publisher","first-page":"436","DOI":"10.1038\/kisup.2013.91","volume":"3","author":"S Fukuma","year":"2013","unstructured":"Fukuma S, Kurita N, Fukagawa M, Akizawa T, Fukuhara S. Impact of cinacalcet introduction on MBD management: the MBD-5D study in Japan. Kidney Int Suppl. 2013;3(5):436\u201341. https:\/\/doi.org\/10.1038\/kisup.2013.91.","journal-title":"Kidney Int Suppl"},{"issue":"1","key":"1139_CR9","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1093\/ndt\/gfm534","volume":"23","author":"M Fukagawa","year":"2008","unstructured":"Fukagawa M, Yumita S, Akizawa T, Uchida E, Tsukamoto Y, Iwasaki M, KRN1493 Study Group, et al. Cinacalcet (KRN1493) effectively decreases the serum intact PTH level with favorable control of the serum phosphorus and calcium levels in Japanese dialysis patients. Nephrol Dial Transplant. 2008;23(1):328\u201335. https:\/\/doi.org\/10.1093\/ndt\/gfm534.","journal-title":"Nephrol Dial Transplant"},{"issue":"1","key":"1139_CR10","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1111\/j.1542-4758.2009.00397.x","volume":"14","author":"Y Gincherman","year":"2010","unstructured":"Gincherman Y, Moloney K, McKee C, Coyne DW. Assessment of adherence to cinacalcet by prescription refil1 rates in hemodialysis patients. Hemodial Int. 2010;14(1):68\u201372. https:\/\/doi.org\/10.1111\/j.1542-4758.2009.00397.x.","journal-title":"Hemodial Int"},{"issue":"1","key":"1139_CR11","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1016\/j.ekir.2016.04.002","volume":"1","author":"KZ Edson","year":"2016","unstructured":"Edson KZ, Wu BM, Iyer A, Goodman W, Skiles GL, Subramanian R. Determination of etelcalcetide biotransformation and hemodialysis kinetics to guide the timing of its dosing. Kidney Int Rep. 2016;1(1):24\u201333. https:\/\/doi.org\/10.1016\/j.ekir.2016.04.002.","journal-title":"Kidney Int Rep."},{"issue":"6","key":"1139_CR12","doi-asserted-by":"publisher","first-page":"620","DOI":"10.1002\/jcph.460","volume":"55","author":"P Chen","year":"2015","unstructured":"Chen P, Melhem M, Xiao J, Kuchimanchi M, Perez Ruixo JJ. Population pharmacokinetics analysis of AMG 416, an allosteric activator of the calcium-sensing receptor, in subjects with secondary hyperparathyroidism receiving hemodialysis. J Clin Pharmacol. 2015;55(6):620\u20138. https:\/\/doi.org\/10.1002\/jcph.460.","journal-title":"J Clin Pharmacol"},{"issue":"2","key":"1139_CR13","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1007\/s40620-019-00677-0","volume":"33","author":"A Bellasi","year":"2020","unstructured":"Bellasi A, Cozzolino M, Malberti F, Cancarini G, Esposito C, Guastoni CM, et al. New scenarios in secondary hyperparathyroidism: etelcalcetide. Position paper of working group on CKD-MBD of the Italian Society of Nephrology. J Nephrol. 2020;33(2):211\u201321. https:\/\/doi.org\/10.1007\/s40620-019-00677-0.","journal-title":"J Nephrol"},{"issue":"3","key":"1139_CR14","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1111\/1744-9987.13434","volume":"24","author":"T Akizawa","year":"2020","unstructured":"Akizawa T, Ikejiri K, Kondo Y, Endo Y, Fukagawa M. Evocalcet: a new oral calcimimetic for dialysis patients with secondary hyperparathyroidism. Ther Apher Dial. 2020;24(3):248\u201357. https:\/\/doi.org\/10.1111\/1744-9987.13434.","journal-title":"Ther Apher Dial"},{"issue":"7","key":"1139_CR15","first-page":"396","volume":"43","author":"J Patel","year":"2018","unstructured":"Patel J, Bridgeman MB. Etelcalcetide (Parsabiv) for secondary hyperparathyroidism in adults with chronic kidney disease on hemodialysis. Pharm Ther. 2018;43(7):396\u20139.","journal-title":"Pharm Ther"},{"issue":"2","key":"1139_CR16","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1001\/jama.2016.19468","volume":"317","author":"GA Block","year":"2017","unstructured":"Block GA, Bushinsky DA, Cheng S, Cunningham J, Dehmel B, Drueke TB, et al. Effect of etelcalcetide vs cinacalcet on serum parathyroid hormone in patients receiving hemodialysis with secondary hyperparathyroidism: a randomized clinical trial. JAMA. 2017;317(2):156\u201364. https:\/\/doi.org\/10.1001\/jama.2016.19468.","journal-title":"JAMA"},{"issue":"10","key":"1139_CR17","doi-asserted-by":"publisher","first-page":"2328","DOI":"10.1172\/JCI119413","volume":"99","author":"JM Ray","year":"1997","unstructured":"Ray JM, Squires PE, Curtis SB, Meloche MR, Buchan AM. Expression of the calcium-sensing receptor on human antral gastrin cells in culture. J Clin Investig. 1997;99(10):2328\u201333. https:\/\/doi.org\/10.1172\/JCI119413.","journal-title":"J Clin Investig"},{"issue":"4","key":"1139_CR18","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0195316","volume":"13","author":"T Kawata","year":"2018","unstructured":"Kawata T, Tokunaga S, Murai M, Masuda N, Haruyama W, Shoukei Y, et al. A novel calcimimetic agent, evocalcet (MT-4580\/KHK7580), suppresses the parathyroid cell function with little effect on the gastrointestinal tract or CYP isozymes in vivo and in vitro. PLoS ONE. 2018;13(4): e0195316. https:\/\/doi.org\/10.1371\/journal.pone.0195316.","journal-title":"PLoS ONE"},{"issue":"11","key":"1139_CR19","doi-asserted-by":"publisher","first-page":"2055","DOI":"10.1016\/j.bmcl.2018.04.055","volume":"28","author":"H Miyazaki","year":"2018","unstructured":"Miyazaki H, Ikeda Y, Sakurai O, Miyake T, Tsubota R, Okabe J, et al. Discovery of evocalcet, a next-generation calcium-sensing receptor agonist for the treatment of hyperparathyroidism. Bioorg Med Chem Lett. 2018;28(11):2055\u201360. https:\/\/doi.org\/10.1016\/j.bmcl.2018.04.055.","journal-title":"Bioorg Med Chem Lett"},{"key":"1139_CR20","doi-asserted-by":"publisher","unstructured":"Kidney Disease: Improving Global Outcomes (KDIGO) CKD-MBD Update Work Group. KDIGO 2017 clinical practice guideline update for the diagnosis, evaluation, prevention, and treatment of chronic kidney disease-mineral and bone disorder (CKD-MBD). Kidney Int Suppl. 2017;7(1):1\u201359. https:\/\/doi.org\/10.1016\/j.kisu.2017.04.001.","DOI":"10.1016\/j.kisu.2017.04.001"},{"issue":"6","key":"1139_CR21","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1053\/j.ajkd.2017.07.019","volume":"70","author":"T Isakova","year":"2017","unstructured":"Isakova T, Nickolas TL, Denburg M, Yarlagadda S, Weiner DE, Guti\u00e9rrez OM, et al. KDOQI US commentary on the 2017 KDIGO clinical practice guideline update for the diagnosis, evaluation, prevention, and treatment of chronic kidney disease-mineral and bone disorder (CKD-MBD). Am J Kidney Dis. 2017;70(6):737\u201351. https:\/\/doi.org\/10.1053\/j.ajkd.2017.07.019.","journal-title":"Am J Kidney Dis"},{"issue":"3","key":"1139_CR22","doi-asserted-by":"publisher","first-page":"358","DOI":"10.7326\/0003-4819-104-3-358","volume":"104","author":"JC Maynard","year":"1986","unstructured":"Maynard JC, Cruz C, Kleerekoper M, Levin NW. Blood pressure response to changes in serum ionized calcium during hemodialysis. Ann Intern Med. 1986;104(3):358\u201361. https:\/\/doi.org\/10.7326\/0003-4819-104-3-358.","journal-title":"Ann Intern Med"},{"issue":"1","key":"1139_CR23","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1053\/ajkd.1998.v32.pm9669433","volume":"32","author":"FM van der Sande","year":"1998","unstructured":"van der Sande FM, Cheriex EC, van Kuijk WH, Leunissen KM. Effect of dialysate calcium concentrations on intradialytic blood pressure course in cardiac-compromised patients. Am J Kidney Dis. 1998;32(1):125\u201331. https:\/\/doi.org\/10.1053\/ajkd.1998.v32.pm9669433.","journal-title":"Am J Kidney Dis"},{"issue":"2","key":"1139_CR24","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1007\/s10741-013-9371-1","volume":"19","author":"DB Newman","year":"2014","unstructured":"Newman DB, Fidahussein SS, Kashiwagi DT, Kennel KA, Kashani KB, Wang Z, et al. Reversible cardiac dysfunction associated with hypocalcemia: a systematic review and meta-analysis of individual patient data. Heart Fail Rev. 2014;19(2):199\u2013205. https:\/\/doi.org\/10.1007\/s10741-013-9371-1.","journal-title":"Heart Fail Rev"},{"issue":"10","key":"1139_CR25","doi-asserted-by":"publisher","first-page":"1479","DOI":"10.1016\/j.mayocp.2017.05.028","volume":"92","author":"H Yarmohammadi","year":"2017","unstructured":"Yarmohammadi H, Uy-Evanado A, Reinier K, Rusinaru C, Chugh H, Jui J, et al. Serum calcium and risk of sudden cardiac arrest in the general population. Mayo Clin Proc. 2017;92(10):1479\u201385. https:\/\/doi.org\/10.1016\/j.mayocp.2017.05.028.","journal-title":"Mayo Clin Proc"}],"container-title":["Clinical Pharmacokinetics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40262-022-01139-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40262-022-01139-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40262-022-01139-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,9,3]],"date-time":"2022-09-03T03:45:30Z","timestamp":1662176730000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40262-022-01139-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6,28]]},"references-count":25,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2022,9]]}},"alternative-id":["1139"],"URL":"https:\/\/doi.org\/10.1007\/s40262-022-01139-w","relation":{},"ISSN":["0312-5963","1179-1926"],"issn-type":[{"value":"0312-5963","type":"print"},{"value":"1179-1926","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,6,28]]},"assertion":[{"value":"4 May 2022","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 June 2022","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Sanwa Kagaku Kenkyusho Co., Ltd. (SKK) sponsored this study. SKK was involved in the collection, management, analysis, and interpretation of the study data.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Fumihlko Koiwa, Keitaro Yokoyama, and Masafumi Fukagawa received honoraria from SKK. Kenji Asano and Daisuke Honda are employees of SKK. Tadao Akizawa received consulting fees from SKK.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest\/competing interests"}},{"value":"The study was approved by the institutional review board of each participating center.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"All subjects provided written informed consent before participating in the study.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Not applicable.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of data and material"}},{"value":"Not applicable.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}},{"value":"JJK, KY, MF, and DH substantially contributed to the analysis and interpretation of the data. FK, KA, and TA substantially contributed to the study design and the acquisition and interpretation of the data. All authors critically revised the report, commented on drafts of the manuscript, and approved the final report.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Authors\u2019 contributions"}}]}}